

CITATION REPORT

List of articles citing

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department

DOI: 10.1186/s12913-018-3751-0
BMC Health Services Research, 2018, 18, 932.

Source: <https://exaly.com/paper-pdf/69940276/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
10	Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department. <i>Journal of Medical Economics</i> , 2019 , 22, 652-661	2.4	3
9	Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz475	1	7
8	Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department. <i>American Journal of Emergency Medicine</i> , 2020 , 38, 321-324	2.9	1
7	Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 53-67	6.2	14
6	Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis. <i>Drugs - Real World Outcomes</i> , 2020 , 7, 20-29	2.2	5
5	Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway. <i>Drugs - Real World Outcomes</i> , 2020 , 7, 30-35	2.2	6
4	Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 107-117	6.2	5
3	Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.. <i>European Journal of Health Economics</i> , 2022 , 1	3.6	1
2	How to manage skin and soft-tissue infections in the emergency department. 2023 , 36, 81-88		0
1	Antibiotic Stewardship in the Emergency Department. 2023 , 43-71		0